Drugs Made In America Acquisition (DMAA) Earnings Analysis
Drugs Made In America Acquisition (DMAA) has no confirmed upcoming earnings date. Trailing P/E 52.15.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does DMAA next report earnings?
No confirmed upcoming earnings date is currently scheduled for DMAA. This page updates as the calendar is published.
DMAA earnings history — beats and misses
No reported earnings history is available for this symbol in our dataset.
DMAA valuation and analyst view
| Trailing P/E | 52.15 |
|---|---|
| Trailing EPS | 0.28942 USD |
| Price / book | 1.05 |
| Dividend yield | 0.00% |
| Market cap | 0.36B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Drugs Made In America Acquisition (DMAA)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for DMAA. This page updates as the calendar is published.
What is DMAA's current P/E ratio and EPS?
DMAA trades at a trailing P/E of 52.15 on trailing EPS of 0.2894156086956522 USD.
What do analysts rate DMAA?
DMAA has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.